| 19.29 -0.9 (-4.46%) | 11-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.79 | 1-year : | 28.06 |
| Resists | First : | 21.22 | Second : | 24.03 |
| Pivot price | 0 | |||
| Supports | First : | 16.7 | Second : | 13.89 |
| MAs | MA(5) : | 19.09  |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 24.03 | Low : | 17.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVMN ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 20.84 - 20.95 | 20.95 - 21.03 |
| Low: | 18.87 - 18.97 | 18.97 - 19.05 |
| Close: | 19.12 - 19.3 | 19.3 - 19.43 |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Thu, 06 Nov 2025
Evommune and BillionToOne climb on trading debut (EVMN:NYSE) - Seeking Alpha
Thu, 06 Nov 2025
Drug developer Evommune targets $150 million in IPO amid government shutdown - The Business Journals
Thu, 06 Nov 2025
Evommune and BillionToOne set IPO prices (EVMN:NYSE) - Seeking Alpha
Tue, 04 Nov 2025
Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market - Smartkarma
Sat, 01 Nov 2025
EVMN - Evommune Inc Stock Price and Quote - Finviz
Fri, 31 Oct 2025
Evommune Joins IPO Class With Planned $160M Raise for Immuno Pipeline - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 7.58e+006 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.455e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 533.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 3e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|